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revealed that the cost increased to €255 when the efﬁ-
ciency of empiric treatment rose from 67% to 80% using
a double dose during 8 weeks. The cost related to treat-
ment varied from €112 to €236 using respectively the
cheapest and the most expensive PPI; as compared to the
actual treatment this resulted in a cost decrease of respec-
tively €138 and €233. Number of days treated while on
“on-demand” therapy also signiﬁcantly inﬂuenced costs:
€171 for 1/7 and €270 for 7/7. CONCLUSIONS: The
cost reduction with the new reimbursement proposal is
robust to changes in efﬁciency rate, in PPI-price and in
duration of “on demand” therapy.
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OBJECTIVE: To compare the cost of UK licensed PPI-
based triple therapies for the eradication of H. pylori
from the perspective of the National Health Service.
METHODS: A recent meta-analysis of trials comparing
all UK licensed PPI-based triple therapies using amoxi-
cillin and clarithromycin over a 7-day period found no
signiﬁcant difference in the rate of H. pylori eradication.
Mean per patient costs were calculated by multiplying the
resource utilisation incurred by their respective national
published unit costs at year 2003 prices. To estimate the
impact of using the least expensive triple therapy on a
typical Primary Care Organisation (PCO), differences in
mean per patient cost were multiplied by the annual inci-
dence of H. pylori compared to current expenditure.
Current expenditure was based on national usage pattern
of the available treatment options. Sensitivity analysis
was conducted to assess the impact of administering
omeprazole 40mg once daily vs omeprazole 20mg twice
daily and the availability of generic omeprazole.
RESULTS: Mean per patient cost for a 7-day esomepra-
zole-based treatment regimen was £34.24, £5.03 lower
than omeprazole-, £2.58 less than lansoprazole- and pan-
toprazole-, and £2.13 lower than rabeprazole-based triple
therapies. The budget impact analysis suggests that a
typical PCO could save up to £4386 per annum if only
esomeprazole-based triple therapy were used for H. pylori
eradication. Sensitivity analyses found the results were
robust to changes in key model parameters. CONCLU-
SIONS: Esomeprazole-based triple therapy is the least
expensive treatment option for the eradication of H.
pylori licensed for use in the UK.
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OBJECTIVE: To conduct a cost consequence analysis 
of EnteryxTM procedure versus surgery (Laparoscopic
Nissen Fundoplication = LNF) in a French public hospi-
tal setting. Nissen Fundoplication is the actual technique
of reference for severe Gastro Esophageal Reﬂux Disease
(GERD) and EnteryxTM procedure is a new inject-
able, endoscopic polymer-based treatment for GERD.
METHODS: A decision tree model was built in DATATM
TreeAge 4.0 to predict the average cost and effectiveness
per patient for each of the treatment strategies. The time
horizon was one year and a French public hospital per-
spective was taken. For both strategies, the efﬁcacy crite-
rion was the complete PPI stop after one year. Efﬁcacy
data on EnteryxTM were taken from the EnteryxTM
multicenter clinical trial. Clinical outcomes with LNF
were derived from the literature and validated by a sur-
gical advisory board. Unit cost data were based on the
French DRG system (PMSI 2000). DRG costs have been
inﬂated by 2.5% and 5% to obtain current year costs. 
At 2.5% rate, procedural cost for EnteryxTM were 
estimated at €2200 (based on DRG 830—ambulatory
endoscopy with anaesthesia) and at €6300 for LNF (DRG
215, 216). RESULTS: After one year, the average cost per
patient was lower for EnteryxTM (2.5%: €3364–5%:
€3541) than for Nissen Fundoplication (2.5%: €6492
€–5%: €6800). The one way sensitivity analysis shows
that the model is most sensitive to the success rate of
EnteryxTM and to the procedural cost. CONCLUSION:
For patients eligible for surgery, EnteryxTM offers a new
less invasive and cheaper alternative compared to LNF.
The savings with EnteryxTM are mainly due to lower
hospital and procedural costs.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD)
is one of the most common chronic disorders of the gas-
trointestinal tract. The aim of this study was to evaluate
the cost of illness in patients affected by GERD visited 
by general practitioners (GPs). METHODS: A cross-
sectional observational multicentre cost of illness study
was conducted in the urban area of Milan. Information
was obtained through a battery of four questionnaires
ﬁlled out by 317 GERD patients consecutively enrolled
by 47 GPs, investigating clinical (severity and frequency
